Join to View Full Profile
1515 Holcombe Blvdunit 1373Houston, TX 77030
Phone+1 713-792-3250
Dr. Navai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityResidency, Urology, 2006 - 2010- McGaw Medical Center of Northwestern UniversityResidency, Surgery, 2004 - 2006
- Northwestern University The Feinberg School of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2026
GA State Medical License 2022 - 2026
TN State Medical License 2022 - 2026
TX State Medical License 2010 - 2026
AL State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
American Board of Urology Urology- Join now to see all
Clinical Trials
- Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging Start of enrollment: 2014 Jun 25
- Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy Start of enrollment: 2018 Jan 11
- Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer Start of enrollment: 2019 Sep 03
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.Patrick Carriere, Omar Alhalabi, Jianjun Gao, Osama Mohamad, Matthew T Campbell
Clinical and Translational Radiation Oncology. 2024-11-01 - 3 citationsChallenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?Amanda A Myers, Wei Shen Tan, Valentina Grajales, Hyunsoo Hwang, Kelly K Bree
European Urology. 2024-10-01 - A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.Matthew T Campbell, Amishi Y Shah, Pavlos Msaouel, Nizar M Tannir, Arlene O Siefker-Radtke
Cancer Research Communications. 2024-09-01
Press Mentions
Why Thousands Travel to Houston from Out of State to Beat CancerApril 7th, 2025- The Scope of the 'Cancer' Label DebateJanuary 30th, 2025
MDACC 2018: Optimizing the Management of cT2N0 DiseaseNovember 11th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
